Sanofi India Limited (BOM:500674)
India · Delayed Price · Currency is INR 3,522.25
+56.75 (1.64%)
At close: Apr 15, 2026
Sanofi India Income Statement
Financials in millions INR. Fiscal year is January - December.
Millions INR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 18,374 | 20,132 | 19,961 | 27,701 | 29,566 | |
Revenue Growth (YoY) | -8.73% | 0.86% | -27.94% | -6.31% | 1.88% |
Cost of Revenue | 9,102 | 9,942 | 9,651 | 12,053 | 13,235 |
Gross Profit | 9,272 | 10,190 | 10,310 | 15,648 | 16,331 |
Selling, General & Admin | 2,045 | 2,598 | 3,050 | 4,414 | 4,836 |
Other Operating Expenses | 2,311 | 2,686 | 2,360 | 4,157 | 3,869 |
Operating Expenses | 4,729 | 5,651 | 5,775 | 8,990 | 9,372 |
Operating Income | 4,543 | 4,539 | 4,535 | 6,658 | 6,959 |
Interest Expense | -17 | -15 | -17 | -17 | -18 |
Interest & Investment Income | 140 | 132 | 436 | 589 | 631 |
Currency Exchange Gain (Loss) | 18 | 22 | 16 | 2 | 5 |
Other Non Operating Income (Expenses) | 23 | 8 | 145 | 122 | 41 |
EBT Excluding Unusual Items | 4,707 | 4,686 | 5,115 | 7,354 | 7,618 |
Merger & Restructuring Charges | -273 | -377 | -77 | - | - |
Gain (Loss) on Sale of Assets | 1 | 5 | -21 | -2 | 66 |
Asset Writedown | - | - | - | -29 | - |
Other Unusual Items | 12 | - | 268 | 1,320 | 4,892 |
Pretax Income | 4,447 | 4,314 | 5,285 | 8,643 | 12,576 |
Income Tax Expense | 1,180 | 1,177 | 1,639 | 2,437 | 3,132 |
Earnings From Continuing Operations | 3,267 | 3,137 | 3,646 | 6,206 | 9,444 |
Earnings From Discontinued Operations | - | 998 | 2,383 | - | - |
Net Income | 3,267 | 4,135 | 6,029 | 6,206 | 9,444 |
Net Income to Common | 3,267 | 4,135 | 6,029 | 6,206 | 9,444 |
Net Income Growth | -20.99% | -31.41% | -2.85% | -34.29% | 97.74% |
Shares Outstanding (Basic) | 23 | 23 | 23 | 23 | 23 |
Shares Outstanding (Diluted) | 23 | 23 | 23 | 23 | 23 |
EPS (Basic) | 141.85 | 179.54 | 261.78 | 269.47 | 410.06 |
EPS (Diluted) | 141.85 | 179.54 | 261.78 | 269.47 | 410.06 |
EPS Growth | -20.99% | -31.41% | -2.85% | -34.29% | 97.74% |
Free Cash Flow | 4,126 | 4,253 | 1,961 | 3,765 | 5,358 |
Free Cash Flow Per Share | 179.15 | 184.67 | 85.15 | 163.48 | 232.65 |
Dividend Per Share | 123.000 | 117.000 | 167.000 | 194.000 | 181.000 |
Dividend Growth | 5.13% | -29.94% | -13.92% | 7.18% | 44.80% |
Gross Margin | 50.46% | 50.62% | 51.65% | 56.49% | 55.24% |
Operating Margin | 24.73% | 22.55% | 22.72% | 24.04% | 23.54% |
Profit Margin | 17.78% | 20.54% | 30.20% | 22.40% | 31.94% |
Free Cash Flow Margin | 22.46% | 21.13% | 9.82% | 13.59% | 18.12% |
EBITDA | 4,862 | 4,852 | 4,847 | 6,984 | 7,537 |
EBITDA Margin | 26.46% | 24.10% | 24.28% | 25.21% | 25.49% |
D&A For EBITDA | 319 | 313 | 312 | 326 | 578 |
EBIT | 4,543 | 4,539 | 4,535 | 6,658 | 6,959 |
EBIT Margin | 24.73% | 22.55% | 22.72% | 24.04% | 23.54% |
Effective Tax Rate | 26.53% | 27.28% | 31.01% | 28.20% | 24.91% |
Revenue as Reported | 18,571 | 20,297 | 20,573 | 28,416 | 30,310 |
Advertising Expenses | 181 | 179 | 236 | 338 | 461 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.